Blueprint Medicines Corp. | Mid-cap | Healthcare
$128.34
0.12%
| Blueprint Medicines Stock Comparison:
Blueprint Medicines vs VertexBlueprint Medicines vs RegeneronBlueprint Medicines vs Roivant SciencesBlueprint Medicines vs Bio-TechneBlueprint Medicines vs Revolution MedicinesBlueprint Medicines vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 508.8M
Gross Profit 488.7M 96.04%
Operating Income -212.0M -41.67%
Net Income -67.1M -13.19%
EPS (Diluted) -$1.07

Balance Sheet Metrics

Total Assets 1.2B
Total Liabilities 881.1M
Shareholders Equity 298.7M
Debt to Equity 2.95

Cash Flow Metrics

Operating Cash Flow -2.0M
Free Cash Flow -197.2M

Revenue & Profitability Trend

Blueprint Medicines Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 508.8M 249.4M 204.0M 180.1M 793.7M
Cost of Goods Sold 20.2M 8.5M 17.8M 17.9M 425.0K
Gross Profit 488.7M 240.8M 186.2M 162.1M 793.3M
Operating Expenses 700.7M 722.9M 723.7M 804.1M 484.6M
Operating Income -212.0M -482.0M -528.6M -634.2M 308.7M
Pre-tax Income -65.9M -506.0M -552.3M -641.1M 314.9M
Income Tax 1.2M 968.0K 5.2M 3.0M 1.1M
Net Income -67.1M -507.0M -557.5M -644.1M 313.9M
EPS (Diluted) -$1.07 -$8.37 -$9.35 -$11.01 $5.59

Income Statement Trend

Blueprint Medicines Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 742.7M 808.4M 1.0B 554.0M 927.8M
Non-Current Assets 437.1M 240.9M 303.3M 698.2M 790.6M
Total Assets 1.2B 1.0B 1.3B 1.3B 1.7B
Liabilities
Current Liabilities 260.8M 214.9M 183.2M 149.8M 130.8M
Non-Current Liabilities 620.4M 703.7M 652.0M 131.7M 117.5M
Total Liabilities 881.1M 918.6M 835.2M 281.5M 248.3M
Equity
Total Shareholders Equity 298.7M 130.6M 514.7M 970.7M 1.5B

Balance Sheet Composition

Blueprint Medicines Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income -67.1M -507.0M -557.5M -644.1M 313.9M
Operating Cash Flow -2.0M -423.7M -493.7M -310.8M 383.0M
Investing Activities
Capital Expenditures -4.6M -16.1M -8.9M -3.1M -3.2M
Investing Cash Flow -47.5M 274.0M -149.5M 32.3M -434.2M
Financing Activities
Dividends Paid - - - - -
Financing Cash Flow 195.4M 97.9M 553.6M 0 582.5M
Free Cash Flow -197.2M -452.9M -511.2M -559.9M 383.9M

Cash Flow Trend

Blueprint Medicines Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -120.00
Forward P/E -136.38
Price to Book 24.19
Price to Sales 14.75
PEG Ratio -136.38

Profitability Ratios

Profit Margin -27.70%
Operating Margin -27.50%
Return on Equity -47.71%
Return on Assets -9.75%

Financial Health

Current Ratio 2.80
Debt to Equity 208.50
Beta 0.83

Per Share Data

EPS (TTM) -$2.51
Book Value per Share $5.30
Revenue per Share $8.85

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
bpmc 8.3B -120.00 24.19 -47.71% -27.70% 208.50
Vertex 114.1B 32.82 6.92 -5.64% -8.91% 10.00
Regeneron 55.3B 13.02 1.84 15.96% 31.94% 9.20
Roivant Sciences 7.8B 1.95 1.71 -12.54% 96.86% 1.93
Bio-Techne 7.9B 60.87 3.92 6.53% 10.89% 20.99
Revolution Medicines 7.5B -11.18 3.59 -36.68% 0.00% 6.46

Financial data is updated regularly. All figures are in the company's reporting currency.